General form of registration statement for all companies including face-amount certificate companies

Condensed Consolidated Statement of Changes in Stockholders' Equity

v3.19.3.a.u2
Condensed Consolidated Statement of Changes in Stockholders' Equity - USD ($)
Common Stock [Member]
Preferred Stock [Member]
Additional Paid-In Capital [Member]
Subscription Receivable [Member]
Accumulated Deficit [Member]
Total
Balance at Dec. 31, 2016 $ 3,175 $ 4,266,825 $ (2,002,772) $ 2,267,229
Balance, shares at Dec. 31, 2016 31,745,242        
Fair value of Heatwurx net liabilities obtained in a reverse merger $ 352 (38,102) (37,750)
Fair value of Heatwurx net liabilities obtained in a reverse merger, shares 3,527,284        
Net loss (1,856,315) (1,856,315)
Balance at Dec. 31, 2017 $ 3,527 4,228,723 (3,859,087) 373,164
Balance, shares at Dec. 31, 2017 35,272,626          
Recognize the fair value of exclusive license intangible asset acquired from CoNCERT in exchange for 2,090,301 common shares of Processa held by Promet   8,000,000 8,000,000
Net loss   (1,096,798) (1,096,798)
Balance at Mar. 31, 2018 $ 3,527   12,228,723 (4,955,884) 7,276,366
Balance, shares at Mar. 31, 2018 35,272,626          
Balance at Dec. 31, 2017 $ 3,527 4,228,723 (3,859,087) 373,164
Balance, shares at Dec. 31, 2017 35,272,626          
Net loss           (3,155,874)
Balance at Sep. 30, 2018 $ 3,867   19,317,036 (1,800,000) (7,014,961) 10,505,942
Balance, shares at Sep. 30, 2018 38,674,265          
Balance at Dec. 31, 2017 $ 3,527 4,228,723 (3,859,087) 373,164
Balance, shares at Dec. 31, 2017 35,272,626          
Recognize the fair value of exclusive license intangible asset acquired from CoNCERT in exchange for 2,090,301 common shares of Processa held by Promet 8,000,000 8,000,000
Conversion of Senior convertible notes for common stock and stock purchase warrants $ 121 2,312,488 2,312,609
Conversion of Senior convertible notes for common stock and stock purchase warrants, shares 1,206,245        
Issuance of common stock units for cash $ 140 2,874,547 2,874,687
Issuance of common stock units for cash, shares 1,402,442        
Issuance of common stock units for a future research funding commitment $ 79 1,631,464 (1,800,000) (168,457)
Issuance of common stock units for a future research funding commitment, shares 792,952        
Stock-based compensation 74,063 74,063
Net loss (3,765,047) (3,765,047)
Balance at Dec. 31, 2018 $ 3,867 19,121,285 (1,800,000) (7,624,134) 9,701,018
Balance, shares at Dec. 31, 2018 38,674,265          
Balance at Mar. 31, 2018 $ 3,527   12,228,723 (4,955,884) 7,276,366
Balance, shares at Mar. 31, 2018 35,272,626          
Conversion of Senior convertible notes for common stock and stock purchase warrants $ 121   2,390,248 2,390,369
Conversion of Senior convertible notes for common stock and stock purchase warrants, shares 1,206,245          
Issuance of common stock units for cash $ 140   2,964,955 2,965,095
Issuance of common stock units for cash, shares 1,402,442          
Issuance of common stock units for a future research funding commitment $ 79   1,682,582 (1,800,000) (117,339)
Issuance of common stock units for a future research funding commitment, shares 792,952          
Net loss   (1,206,255) (1,206,255)
Balance at Jun. 30, 2018 $ 3,867   19,266,508 (1,800,000) (6,162,139) 11,308,236
Balance, shares at Jun. 30, 2018 38,674,265          
Stock-based compensation   50,528 50,528
Net loss   (852,822) (852,822)
Balance at Sep. 30, 2018 $ 3,867   19,317,036 (1,800,000) (7,014,961) 10,505,942
Balance, shares at Sep. 30, 2018 38,674,265          
Balance at Dec. 31, 2018 $ 3,867 19,121,285 (1,800,000) (7,624,134) 9,701,018
Balance, shares at Dec. 31, 2018 38,674,265          
Stock-based compensation   58,559 58,559
Payments made by investor for clinical trial costs   115,000 115,000
Net loss   (750,832) (750,832)
Balance at Mar. 31, 2019 $ 3,867   19,179,844 (1,685,000) (8,374,966) 9,123,745
Balance, shares at Mar. 31, 2019 38,674,265          
Balance at Dec. 31, 2018 $ 3,867 19,121,285 (1,800,000) (7,624,134) 9,701,018
Balance, shares at Dec. 31, 2018 38,674,265          
Net loss           (2,583,433)
Balance at Sep. 30, 2019 $ 3,840   18,874,406 (10,207,567) 8,670,679
Balance, shares at Sep. 30, 2019 38,404,530          
Balance at Mar. 31, 2019 $ 3,867   19,179,844 (1,685,000) (8,374,966) 9,123,745
Balance, shares at Mar. 31, 2019 38,674,265          
Stock-based compensation   66,476 66,476
Payments made by investor for clinical trial costs   280,927 280,927
Net loss   (969,077) (969,077)
Balance at Jun. 30, 2019 $ 3,867   19,246,320 (1,404,073) (9,344,043) 8,502,071
Balance, shares at Jun. 30, 2019 38,674,265          
Conversion of Senior convertible notes for common stock and stock purchase warrants $ 13   258,917 258,930
Conversion of Senior convertible notes for common stock and stock purchase warrants, shares 126,741          
Stock-based compensation   269,129 269,129
Payments made by investor for clinical trial costs   504,073 504,073
Pledged shares of common stock forfeited upon revised research funding commitment $ (40)   (899,960) 900,000
Pledged shares of common stock forfeited upon revised research funding commitment, shares (396,476)          
Net loss   (863,524) (863,524)
Balance at Sep. 30, 2019 $ 3,840   $ 18,874,406 $ (10,207,567) $ 8,670,679
Balance, shares at Sep. 30, 2019 38,404,530